This funding opportunity supports investigator-initiated research to analytically and clinically validate molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, treatment response, and prevention. It funds a two-phase process: UH2 for analytical validation within 2 years, and UH3 for clinical validation up to 3 years using well-annotated biospecimens. Projects may include assay harmonization across labs and require multidisciplinary teams including oncologists and statisticians.
Eligible applicants include public and private higher education institutions, nonprofits, tribal organizations, government entities, and small businesses in the United States. Specific eligibility details are provided in the full announcement.
